Federica Vitarelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Federica Vitarelli has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Valerio Leoni
Laboratory of Clinical Pathology and Toxicology, Hospital Pio XI of Desio, ASST Brianza and School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
2 shared publications - Amir Mohammad Malvandi
Laboratory of Experimental Biochemistry & Molecular Biology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy
1 shared publication - Andrea Civra
Department of Clinical and Biological Sciences, University of Turin, Orbassano, Turin, 10043, Italy
1 shared publication - Carlo Brogna
Craniomed group srl, Montemiletto, 83038
1 shared publication - Claudio Caccia
Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
1 shared publication David Lembo
Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano (Turin), Italy
1 shared publication
Latest Publications
- 1 December 2023
- Vol. 27 (6 Suppl) , 114-118
Unraveling the complexity of anti-doping analysis: reassessing meldonium detection and doping verdicts in a case study.
The precision and accuracy of mass spectrometry (MS) made it a fundamental tool in anti-doping analysis. High-resolution (HR) mass spectrometers significantly improved compound identification. This study systematically analyzes data from an athlete (Subject 1) who tested positive for meldonium and compares it with data from a healthy volunteer (Subject 2) to examine the correctness of the doping verdict. The documentation related to Subject 1 was thoroughly processed and analyzed. A study involving a volunteer (Subject 2) replicated Subject 1 regimen and urine sample collection for data alignment with anti-doping results, with Subject 2 reporting not using meldonium. The anti-doping agency's analysis of Subject 1 showed the presence of meldonium at a concentration close to the established cut-off level. However, a closer examination revealed that one specific ion, crucial for meldonium identification, was absent from the mass spectra. Analyzing Subject 2 data, using the same methodology, the absence of the specific ion was confirmed, even though the volunteer did not consume meldonium. The European directive and the method that was validated and cited by the anti-doping agency identified meldonium on at least four specific ions, whereas the anti-doping analysis used only three ions. This discrepancy compromises the specificity of meldonium identification. To enhance the analytical methodology, two strategic interventions are suggested: adjusting the meldonium cut-off value and expanding the analysis to include meldonium metabolites. By addressing these avenues, the precision of meldonium detection and doping verdicts can be improved. In conclusion, this study challenges the anti-doping agency's verdict and prompts a reevaluation of meldonium detection methodologies in anti-doping measures.
- 1 December 2023
- Vol. 27 (6 Suppl) , 114-118
Unraveling the complexity of anti-doping analysis: reassessing meldonium detection and doping verdicts in a case study.
The precision and accuracy of mass spectrometry (MS) made it a fundamental tool in anti-doping analysis. High-resolution (HR) mass spectrometers significantly improved compound identification. This study systematically analyzes data from an athlete (Subject 1) who tested positive for meldonium and compares it with data from a healthy volunteer (Subject 2) to examine the correctness of the doping verdict. The documentation related to Subject 1 was thoroughly processed and analyzed. A study involving a volunteer (Subject 2) replicated Subject 1 regimen and urine sample collection for data alignment with anti-doping results, with Subject 2 reporting not using meldonium. The anti-doping agency's analysis of Subject 1 showed the presence of meldonium at a concentration close to the established cut-off level. However, a closer examination revealed that one specific ion, crucial for meldonium identification, was absent from the mass spectra. Analyzing Subject 2 data, using the same methodology, the absence of the specific ion was confirmed, even though the volunteer did not consume meldonium. The European directive and the method that was validated and cited by the anti-doping agency identified meldonium on at least four specific ions, whereas the anti-doping analysis used only three ions. This discrepancy compromises the specificity of meldonium identification. To enhance the analytical methodology, two strategic interventions are suggested: adjusting the meldonium cut-off value and expanding the analysis to include meldonium metabolites. By addressing these avenues, the precision of meldonium detection and doping verdicts can be improved. In conclusion, this study challenges the anti-doping agency's verdict and prompts a reevaluation of meldonium detection methodologies in anti-doping measures.
- Open Access
- 1 July 2022
- Published by Bioscientifica in Redox Experimental Medicine
- Vol. 2022 (1) , 1-7
Determination of plasma and tissue distribution of 27-hydroxycholesterol after a single oral administration in a mouse model
The side chain 27-hydroxycholesterol (27OHC) has been reported to inhibit the replication of several pathogen viruses, including Herpes Simplex virus, Rhinovirus, Rotavirus and SARS-CoV-2, in in vitro and ex vivo models. Objective: in view of a future potential therapeutic use of 27-hydroxycholesterol 27OHC, a pilot pharmacokinetic study was set up. Methods: this active substance was complexed with 2-hydroxypropyl-β-cyclodextrin and orally administered in a single dose to CD1 male mice, then evaluating its recovery in plasma and a few tissues up to 24 h post-treatment. Results: the absorption of the oxysterol by the small intestine was moderate, due to its physicochemical properties, but still relevant and rapid, showing a peak 1 hour after supplementation and being almost completed 24 hours after treament. 27-Hydroxycholesterol 27OHC appeared to be a high hepatic extraction drug, possibly with an extrahepatic component contributing to the total clearance. Conclusions: following the oral 25 mg/kg dosing, plasma levels of 27-hydroxycholesterol 27OHC showed an average steady-state concentration similar to that inhibiting in vitro the replication of all the viruses tested so far. Significance: here reported are the first pharmacokinetic data relative to a natural oxysterol administered per os. Data that should contribute to further elucidate oxysterols pathophysiology and guide non-clinical studies aiming at investigating possible therapeutic use of 27OHC or its analogs.
- 1 July 2022
- Published by Bioscientifica in Redox Experimental Medicine
- Vol. 2022 (1) , 1-7
Open AccessDetermination of plasma and tissue distribution of 27-hydroxycholesterol after a single oral administration in a mouse model
The side chain 27-hydroxycholesterol (27OHC) has been reported to inhibit the replication of several pathogen viruses, including Herpes Simplex virus, Rhinovirus, Rotavirus and SARS-CoV-2, in in vitro and ex vivo models. Objective: in view of a future potential therapeutic use of 27-hydroxycholesterol 27OHC, a pilot pharmacokinetic study was set up. Methods: this active substance was complexed with 2-hydroxypropyl-β-cyclodextrin and orally administered in a single dose to CD1 male mice, then evaluating its recovery in plasma and a few tissues up to 24 h post-treatment. Results: the absorption of the oxysterol by the small intestine was moderate, due to its physicochemical properties, but still relevant and rapid, showing a peak 1 hour after supplementation and being almost completed 24 hours after treament. 27-Hydroxycholesterol 27OHC appeared to be a high hepatic extraction drug, possibly with an extrahepatic component contributing to the total clearance. Conclusions: following the oral 25 mg/kg dosing, plasma levels of 27-hydroxycholesterol 27OHC showed an average steady-state concentration similar to that inhibiting in vitro the replication of all the viruses tested so far. Significance: here reported are the first pharmacokinetic data relative to a natural oxysterol administered per os. Data that should contribute to further elucidate oxysterols pathophysiology and guide non-clinical studies aiming at investigating possible therapeutic use of 27OHC or its analogs.